p14Arf acts as an antagonist of HMGA2 in senescence of mesenchymal stem cells-implications for benign tumorigenesis

Genes Chromosomes and Cancer

Volumn 50, Issue 7, 2011, Pages 489-498

  Markowski, Dominique Nadine ^a   Winter, Nina ^a   Meyer, Frauke ^b   von Ahsen, Inga ^b   Wenk, Heiner ^c   Nolte, Ingo ^b   Bullerdiek, Jörn ^a,b  

^a UNIVERSITY OF BREMEN   (Germany)

^b UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^c Clinical Center Bremen Nord   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; HIGH MOBILITY GROUP A2 PROTEIN; NUTLIN 3; PROTEIN P21; PROTEIN P53; SMALL INTERFERING RNA;

ADIPOSE TISSUE; ANIMAL TISSUE; ARTICLE; BENIGN TUMOR; CARCINOGENESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MESENCHYMAL STEM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; SENESCENCE; UPREGULATION; ANIMAL; CELL AGING; CELL PROLIFERATION; CYTOLOGY; DOG; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASM; REGULATOR GENE; TUMOR CELL LINE;

ANIMALS; CELL AGING; CELL LINE, TUMOR; CELL PROLIFERATION; DOGS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REGULATOR; HMGA2 PROTEIN; HUMANS; MESENCHYMAL STEM CELLS; NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 79955644464     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20871     Document Type: Article

References (27)

1. Ashar HR, Fejzo M, Tkachenko A, Zhou X, Fletcher JA, Weremowicz S, Morton CC, Chada K. 1995. Disruption of the architctural factor HMGI-C: DNA-binding AT hook motifs fused in lipomas to distinct transcriptional regulatory domains. Cell 82: 57-64.
2. Ayoubi TA, Jansen E, Meulemans SM, Van de Ven WJ. 1999. Regulation of HMGIC expression: An architectural transcription factor involved in growth control and development. Oncogene 18: 5076-5087.
3. Bunnell BA, Flaat M, Gagliardi C, Patel B, Ripoll C. 2008. Adipose-derived stem cells: Isolation, expansion and differentiation. Methods 45: 115-120.
4. Buysse K, Reardon W, Mehta L, Costa T, Fagerstrom C, Kingsbury DJ, Anadiotis G, McGillivray BC, Hellemans J, de Leeuw N, de Vries BB, Speleman F, Menten B, Mortier G. 2009. The 12q14 microdeletion syndrome: Additional patients and further evidence that HMGA2 is an important genetic determinant for human height. Eur J Med Genet 52: 101-107.
5. Fusco A, Fedele M. 2007. Roles of HMGA proteins in cancer. Nat Rev Cancer 7: 899-910.
6. Gorzelniak K, Janke J, Engeli S, Sharma AM. 2001. Validation of endogenous controls for gene expression studies in human adipocytes and preadipocytes. Horm Metab Res 33: 625-627.
7. Gross KL, Neskey DM, Manchanda N, Weremowicz S, Kleinman MS, Nowak RA, Ligon AH, Rogalla P, Drechsler K, Bullerdiek J, Morton CC. 2003. HMGA2 expression in uterine leiomyomata and myometrium: Quantitative analysis and tissue culture studies. Genes Chromosomes Cancer 38: 68-79.
8. Hammond SM, Sharpless NE. 2008. HMGA2, microRNAs, and stem cell aging. Cell 135: 1013-1016.
9. Hirning-Folz U, Wilda M, Rippe V, Bullerdiek J, Hameister H. 1998. The expression pattern of the Hmgic gene during development. Genes Chromosomes Cancer 23: 350-357.
10. Klemke M, Meyer A, Nezhad MH, Bartnitzke S, Drieschner N, Frantzen C, Schmidt EH, Belge G, Bullerdiek J. 2009. Overexpression of HMGA2 in uterine leiomyomas points to its general role for the pathogenesis of the disease. Genes Chromosomes Cancer 48: 171-178.
11. Lee S, Jung JW, Park SB, Roh K, Lee SY, Kim JH, Kang SK, Kang KS. 2011. Histone deacetylase regulates high mobility group A2-targeting microRNAs in human cord blood-derived multipotent stem cell aging. Cell Mol Life Sci 68: 325-336.
12. Li O, Vasudevan D, Davey CA, Dröge P. 2006. High-level expression of DNA architectural factor HMGA2 and its association with nucleosomes in human embryonic stem cells. Genesis 44: 523-529.
13. Ligon AH, Moore SD, Parisi MA, Mealiffe ME, Harris DJ, Ferguson HL, Quade BJ, Morton CC. 2005. Constitutional rearrangement of the architectural factor HMGA2: A novel human phenotype including overgrowth and lipomas. Am J Hum Genet 76: 340-348.
14. Mari F, Hermanns P, Giovannucci-Uzielli ML, Galluzzi F, Scott D, Lee B, Renieri A, Unger S, Zabel B, Superti-Furga A. 2009. Refinement of the 12q14 microdeletion syndrome: primordial dwarfism and developmental delay with or without osteopoikilosis. Eur J Hum Genet 17: 1141-1147.
15. Markowski DN, von Ahsen I, Nezhad MH, Wosniok W, Helmke BM, Bullerdiek J. 2010. HMGA2 and the p19Arf-TP53-CDKNIA axis: A delicate balance in the growth of uterine leiomyomas. Genes Chromosomes Cancer 49: 661-668.
16. Miyazawa J, Mitoro A, Kawashiri S, Chada KK, Imai K. 2004. Expression of mesenchyme-specific gene HMGA2 in squamous cell carcinomas of the oral cavity. Cancer Res 64: 2024-2029.
17. Nishino J, Kim I, Chada K, Morrison SJ. 2008. Hmga2 promotes neural stem cell self-renewal in young but not old mice by reducing p16Ink4a and p19Arf expression. Cell 135: 227-239.
18. Planat-Benard V, Silvestre JS, Cousin B, André M, Nibbelink M, Tamarat R, Clergue M, Manneville C, Saillan-Barreau C, Duriez M, Tedgui A, Levy B, Pénicaud L, Casteilla L. 2004. Plasticity of human adipose lineage cells toward endothelial cells: Physiological and therapeutic perspectives. Circulation 109: 656-663.
19. Rogalla P, Drechsler K, Frey G, Hennig Y, Helmke B, Bonk U, Bullerdiek J. 1996. HMGI-C expression patterns in human tissues. Implications for the genesis of frequent mesenchymal tumors. Am J Pathol 149: 775-759.
20. Rogalla P, Drechsler K, Kazmierczak B, Rippe V, Bonk U, Bullerdiek J. 1997. Expression of HMGI-C, a member of the high mobility group protein family, in a subset of breast cancers: relationship to histologic grade. Mol Carcinog 19: 153-156.
21. Sanna S, Jackson AU, Nagaraja R, Willer CJ, Chen WM, Bonnycastle LL, Shen H, Timpson N, Lettre G, Usala G, Chines PS, Stringham HM, Scott LJ, Dei M, Lai S, Albai G, Crisponi L, Naitza S, Doheny KF, Pugh EW, Ben-Shlomo Y, Ebrahim S, Lawlor DA, Bergman RN, Watanabe RM, Uda M, Tuomilehto J, Coresh J, Hirschhorn JN, Shuldiner AR, Schlessinger D, Collins FS, Davey Smith G, Boerwinkle E, Cao A, Boehnke M, Abecasis GR, Mohlke KL. 2008. Common variants in the GDF5-UQCC region are associated with variation in human height. Nat Genet 40: 198-203.
22. Schoenmakers EF, Wanschura S, Mols R, Bullerdiek J, Van den Berghe H, Van de Ven WJ. 1995. Recurrent rearrangements in the high mobility group protein gene, HMGI-C, in benign mesenchymal tumours. Nat Genet 10: 436-444.
23. Spengler S, Schönherr N, Binder G, Wollmann HA, Fricke-Otto S, Mühlenberg R, Denecke B, Baudis M, Eggermann T. 2010. Submicroscopic chromosomal imbalances in idiopathic Silver-Russell syndrome (SRS): The SRS phenotype overlaps with the 12q14 microdeletion syndrome. J Med Genet 47: 356-360.
24. Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, Menssen A, Meister G, Hermeking H. 2007. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 6: 1586-1593.
25. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA. 2004. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303: 844-848.
26. Weedon MN, Lettre G, Freathy RM, Lindgren CM, Voight BF, Perry JR, Elliott KS, Hackett R, Guiducci C, Shields B, Zeggini E, Lango H, Lyssenko V, Timpson NJ, Burtt NP, Rayner NW, Saxena R, Ardlie K, Tobias JH, Ness AR, Ring SM, Palmer CN, Morris AD, Peltonen L, Salomaa V; Diabetes Genetics Initiative; Wellcome Trust Case Control Consortium, Davey Smith G, Groop LC, Hattersley AT, McCarthy MI, Hirschhorn JN, Frayling TM. 2007. A common variant of HMGA2 is associated with adult and childhood height in the general population. Nat Genet 39: 1245-1250.
27. Zhang Y, Xiong Y, Yarbrough WG. 1998. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92: 725-734.